Thus, the results of this investigation confirm those published previously and demonstrate that octreotide LAR fulfils all the requirements for the primary treatment of acromegaly because it can reverse tumour growth, produce a sustained suppression of the elevated levels of GH and IGF-1 and control the symptoms of the disease. This evidence concerns the gene IGF1 and acromegaly.